Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | PKLR | P30613 | 4/20 | 0.38 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | CASP9 | P55211 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5129420 | 0.89 | CHRM4 (0.37) | LOXEPHX2ALDH1A1CASP3CASP2 | |
| SCHEMBL2566833 | 0.87 | ALDH1A1 (0.43) | LOXALDH1A1CYP2D6CASP3CASP2 | |
| SCHEMBL5128726 | 0.86 | PKM (0.36) | LOXEPHX2ALDH1A1CASP3CASP2 | |
| SCHEMBL5127118 | 0.84 | PKLR (0.42) | LOXPKLRCYP46A1EPHX2ALDH1A1 | |
| SCHEMBL5132580 | 0.83 | EPHX2 (0.35) | LOXEPHX2PKM | |
| SCHEMBL5129027 | 0.83 | CCR1 (0.39) | EPHX2CASP3CASP7PKM | |
| SCHEMBL3828007 | 0.83 | HCRTR1 (0.39) | PKLRCYP46A1EPHX2ALDH1A1TACR1 | |
| SCHEMBL5125891 | 0.83 | PKLR (0.41) | PKLRCYP46A1EPHX2TACR1CASP3 | |
| SCHEMBL5125464 | 0.82 | PKLR (0.47) | PKLRALDH1A1PKM | |
| SCHEMBL3825264 | 0.82 | MEN1 (0.43) | ALDH1A1CYP2D6CASP3CASP7PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | claimed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | LOX 1976/4885PKLR 746/4885CYP46A1 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.